NanoViricides, Inc. (NYSE American: NNVC) announced continued progress in advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The proposed trial, which will evaluate an oral gummies formulation, has received approval from the DRC Pillar Committee, with preparations underway for ethics and regulatory submissions.
NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies are difficult to deploy. The company highlighted the severity of the outbreak, citing 1,561 confirmed cases and 506 deaths in the DRC as of July 6, while emphasizing that no approved treatment or vaccine exists for the Bundibugyo strain.
NanoViricides believes NV-387’s broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains. Notably, the same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product shipped to the country for that study.
For more details, view the full press release at https://ibn.fm/LaNwF.
